The combination of YTHDF2 and YAP mRNA reduces the stability of mRNA, while YTHDF2 recruits AGO2 (argonaute RISC catalytic component 2) to promote the degradation of YAP mRNA, affecting the production of related tumor factors and inhibiting the occurrence of tumors in breast cancer [122,123]. The gene discussed is AGO2; the disease is breast carcinoma.